{"id":483917,"title":"Overview: Annex 3A to the Good manufacturing practices guide - Schedule C drugs (GUI-0026) - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-01-06","captureTimestamp":"2026-01-06T22:39:18.470000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/good-manufacturing-practices/guidance-documents/annex-3-current-edition-guidelines-schedule-drugs-0026.html?wbdisable=true","snippet":"Annex 3A to the Good manufacturing practices guide - Schedule C drugs (GUI-0026): Overview Date implemented: July 04, 2024 Replaces: Guidance Document Annex 3 to the Current Edition of the Good Manufacturing Practices Guidelines - Schedule C Drugs (GUI-0026) , November 19, 2010…","rawSnapshotUrl":"/api/snapshots/raw/483917","browseUrl":"https://replay.healtharchive.ca/job-6/20260106223918/https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/good-manufacturing-practices/guidance-documents/annex-3-current-edition-guidelines-schedule-drugs-0026.html?wbdisable=true#ha_snapshot=483917","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}